Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial
- 15 November 2011
- journal article
- clinical trial
- Published by Wiley in International Journal of Andrology
- Vol. 35 (2), 190-195
- https://doi.org/10.1111/j.1365-2605.2011.01226.x
Abstract
Extracorporeal shock wave therapy improves erectile function in patients with Peyronie's disease. However, erectile dysfunction still persists in many cases. We aimed to investigate the effects of extracorporeal shock wave therapy plus tadalafil 5 mg once daily in the management of patients with Peyronie's disease and erectile dysfunction not previously treated. One hundred patients were enrolled in a prospective, randomized, controlled study. Patients were randomly allocated to receive either extracorporeal shock wave therapy alone for 4 weeks (n = 50) or extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks (n = 50). Main outcome measures were: erectile function (evaluated through the shortened version of the International Index of Erectile Function), pain during erection (evaluated through a Visual Analog Scale), plaque size, penile curvature and quality of life (evaluated through an internal questionnaire). Follow-up evaluations were performed after 12 and 24 weeks. In both groups, at 12 weeks follow-up, mean Visual Analog Scale score, mean International Index of Erectile Function score and mean quality of life score ameliorated significantly while mean plaque size and mean curvature degree were unchanged. Intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and quality of life score in patients receiving the combination. After 24 weeks, intergroup analysis revealed a significantly higher mean International Index of Erectile Function score and mean quality of life score in patients that received extracorporeal shock wave therapy plus tadalafil. In conclusion extracorporeal shock wave therapy plus tadalafil 5 mg once daily may represent a valid conservative strategy for the management of patients with Peyronie's disease and erectile dysfunction.Keywords
This publication has 26 references indexed in Scilit:
- Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategyNature Reviews Urology, 2010
- Impact of Peyronie's Disease on Sexual and Psychosocial Functioning: Qualitative Findings in Patients and ControlsThe Journal of Sexual Medicine, 2008
- Peyronie’s Disease: Can We Prevent Disease Progression?European Urology, 2006
- Effects of long‐term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's diseaseBJU International, 2006
- Comparison of Efficacy, Safety, and Tolerability of On-Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile DysfunctionThe Journal of Sexual Medicine, 2005
- An alternative non-invasive treatment for Peyronie's diseaseInternational braz j urol, 2004
- Questionable Efficacy of Extracorporeal Shock Wave Therapy for Peyronie’s Disease:: Results of a Prospective ApproachJournal of Urology, 2004
- A New Biopsy Technique to Investigate Peyronie's Disease Associated Histologic Alterations: Results with Two Different Forms of TherapyEuropean Urology, 2002
- EXTRACORPOREAL SHOCK WAVE THERAPY IN ORTHOPEDICSInternational Journal of Technology Assessment in Health Care, 2000
- Sexual Dysfunction in Peyronie's Disease: An Analysis of 222 Patients Without Previous Local Plaque TherapyJournal of Urology, 1997